Gilead and Vir Biotechnology Establish Clinical Collaboration to Explore Combination Strategies for Functional Cure for Chronic Hepatitis B Virus First Phase 2 Clinical Trial to Combine Immunomodulation and Antigen Suppression Approaches in HBV Cure Research — Gilead Sciences, Inc. and Vir Biotechnology, Inc. today announced that the companies have entered into a clinical collaboration to evaluate novel therapeutic combination strategies aimed at developing a functional cure for chronic hepatitis B virus . The companies plan to initiate a Phase 2 trial … — First Phase 2 Clinical Trial to Combine Immunomodulation and Antigen Suppression Approaches in HBV Cure Research — Gilead Sciences, Inc. (NASDAQ: GILD) and Vir Biotechnology, Inc. (NASDAQ: VIR) today announced that the companies have entered into a clinical collaboration to evaluate novel therapeutic combination strategies aimed at developing a functional cure for chronic hepatitis B virus (HBV).